2022 Chronic Pain Clinical Trials 
The Cannigma
MAY 13, 2022
One of the most common uses of medical cannabis is to treat chronic pain. In fact, modern research on cannabis and pain dates back to before 1975. Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. How cannabis can help with pain.
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 10, 2022
11 May 2022. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. Pain, anxiety and sleep issues are often interconnected – chronic pain can also cause mental health and sleep issues.”. Here’s the Uni of Sydney press release.
SpeedWeed
AUGUST 4, 2021
After watching my brother self-medicate for his chronic pain for decades, I didn’t understand how cannabis was important to him as a medicine. I always thought he used his chronic pain as an “excuse” to self-administer what I thought was a toxic drug. . in 2014, I watched my brother walk into a cannabis clinic.
Cannabis Law Report
MAY 14, 2022
13 May 2022. By 2022, it is now difficult to find a high street or retail centre between John o’ Groats and Land’s End without CBD products for sale. However, observational studies have their limitations, which is why most have recently welcomed with open arms the UK Health Research Authority approved trial, Canpain.
The Cannigma
DECEMBER 12, 2022
Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.
Cannabis Law Report
OCTOBER 6, 2021
Under the terms of this agreement, Sinclair Research will perform preclinical animal studies including method, dosage and toxicity as part of the enabling trials for an Investigational New Drug Application (“IND”) for AnQlar, as required by the U.S. The studies are expected to begin in January of 2022.
Expert insights. Personalized for you.
111 
Let's personalize your content